Latest news with #RefluxStop™
Yahoo
5 days ago
- Business
- Yahoo
Implantica announces that UK NICE has published positive recommendations for the RefluxStop™ procedure in the NHS public hospitals
VADUZ, Liechtenstein, June 4, 2025 /PRNewswire/ -- Implantica AG (publ.), providing the unique device RefluxStop™ for the treatment of acid reflux, announces that the world-renowned National Institute for Healthcare Excellence (NICE) payer advisory agency for NHS public hospitals in the UK has published positive Interventional Procedures Guidance (IPG) recommendations on the RefluxStop™ procedure, wherein GORD/GERD patients with Ineffective Oesophageal Motility (IOM/IEM) are allowed to be operated with RefluxStop procedure in the public healthcare system, following its guidelines and special arrangements. In the treatment field of acid reflux up to 40-50%1 of the 1 billion sufferers have IOM/IEM. Therefore, NICE IPG recommendations could transform the lives of millions of patients in the UK and worldwide, given NICE's global influence on health policy development. The IOM/IEM condition is largely untreatable with traditional standard of care. Mr. Ahmed Ahmed, Consultant Surgeon at St. Mary's Hospital, Imperial College NHS Health Trust says, "The positive NICE guidance for use of RefluxStop is a major victory for GORD patients. This decision empowers NHS Anti-Reflux Surgeons to continue delivering cutting-edge care while contributing to the growing body of evidence supporting RefluxStop procedure as a transformative solution for GORD. My patients have heard about RefluxStop procedure as they seek a solution for GORD and ask for it specifically by name. It will be very reassuring for GORD patients to have this supporting evidence-based guidance." Another leading surgeon in the NHS public hospitals, Mr. Fergus Noble, Consultant Surgeon at University Hospital Southampton NHS Foundation Trust, adds, "NICE's new guidelines are crucial for the broader use of a new procedure in the NHS. I'm proud to be a part of this important step forward in expanding the landscape of anti-reflux surgical options for patients with GORD and IOM. Unlike traditional anti-reflux surgeries, the RefluxStop procedure does not rely on encircling the oesophagus, making the durable benefits of a surgical treatment for GORD available to desperate patients who have struggled with the painful symptoms of combined GORD and IOM with poor motility for years." Inventor of the RefluxStop™ procedure, CEO and Founder of Implantica, Dr. Peter Forsell says, "We would like to thank NICE for their independent multidisciplinary assessment of the RefluxStop procedure and invaluable efforts to recognize the excellent safety and efficacy of the innovative RefluxStop™ procedure for use in NHS public hospitals. This recommendation for GORD/GERD patients with IOM marks the start of a global paradigm shift in the surgical treatment of acid reflux, with the NHS UK taking the lead." 1. Shih-Chi Ho et al., Ineffective esophageal motility is a primary motility disorder in gastroesophageal reflux disease. Digestive Diseases and Sciences, 2002. 47(3): 652-6 For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@ The information was sent for publication, through the agency of the contact person set out above, on June 04, 2025, at 08:00 a.m. (CET). About Implantica Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information. About RefluxStop™ RefluxStop™ is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It's unique mechanism of action differentiates it from standard of care and current surgical solutions. Longer established surgical options for GORD involve encircling the food passageway to support the lower oesophageal sphincter's closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit. In contrast, the RefluxStop™ device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower oesophageal sphincter in its original, natural position. The RefluxStop™ mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux. Newsroomhttps:// Communityhttps:// Media Contact:Implantica AGJuanita Eberhart, VP Marketing & AdvocacyM: +1 This information was brought to you by Cision The following files are available for download: Implantica announces that UK NICE has published positive recommendations for the RefluxStop™ procedure in the NHS public Hospitals logo transparent 1 8 ReluxStop Product View original content:
Yahoo
14-02-2025
- Health
- Yahoo
Implantica publishes Year-end Report, January - December 2024 (Q4)
VADUZ, Liechtenstein, Feb. 14, 2025 /PRNewswire/ -- RefluxStop™ FDA Milestone Significant events in the fourth quarter Submitted extensive clinical Module 2 of the 3 module-process in the Premarket Approval (PMA) application to U.S. FDA. Most crucial module containing clinical portion including 5-year long-term follow-up of CE mark pivotal study Reached a milestone of the first 1,000 RefluxStop™ procedures performed. Over 40 leading anti-reflux hospitals across Europe actively perform the RefluxStop™ procedure today Expansion in the UK NHS public hospital network continued with Chelsea & Westminster Hospital in London joining the RefluxStop™ centers Highly successful 3rd Global Annual RefluxStop™ meeting conducted in London, attended by 110+ anti-reflux surgeons and GI doctors - almost three times the amount that attended last year - from all over Europe, US and Canada Health economic study from Sweden performed in partnership with Prof. Lars Lundell from Karolinska Institute was published and shows RefluxStop™ is a highly cost effective long-term alternative for the Sweden Healthcare System Significant events after the end of the period Module 1 was accepted and closed by U.S. FDA in our RefluxStop™ Premarket Approval (PMA) application FDA completed its review of the PMA Clinical Module 2 and provided its written feedback, which the company considers to be very positive and will continue to work with FDA to bring RefluxStop to the U.S. market as soon as possible Results from the largest real-world RefluxStop™ study published, involving 79 patients for up to 17 months follow-up in Germany showing median improvement in quality of life questionnaire, GERD-HRQL of 100% World-leading and largest hospital in Spain, La Paz University Hospital in Madrid, performed their first RefluxStop™ surgeries, representing the 12th center of excellence in Spain to be onboarded Abstract showing the cost-effectiveness analysis for RefluxStop™ in Italy won the prestigious Top 5% Award at the leading payer health-economics congress, ISPOR Fourth quarter financial summary Net sales decreased 13% to TEUR 442 (508) (due to trial devices, see full year). Adjusted gross margin amounted to 90% (92%). Impairment expense relating to capitalized R&D and patents of TEUR 1,669 (0) impacting EBIT. Operating loss (EBIT) increased to TEUR 7,174 (6,942). Loss after tax amounted to TEUR 7,339 (8,734). Basic and diluted loss per Class A share amounted to EUR 0.10 (0.12). Cash as at the end of the period amounted to MEUR 64.6. Full year financial summary Net sales increased 38% to TEUR 1,936 (1,408). Adjusted gross margin amounted to 92% (94%). Operating loss (EBIT) increased to TEUR 25,466 (21,840). Loss after tax amounted to TEUR 23,686 (24,502). Basic and diluted loss per Class A share amounted to EUR 0.34 (0.34). Telephone conference Implantica will hold a teleconference on 14 February 2025 at 15:00 (CET) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast: Dial-in:numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference For further information, please contact: Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@ This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-02-14 08:00 CET. About Implantica Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information. This information was brought to you by Cision The following files are available for download: Implantica Q4 2024 ENG Implantica publishes Year-end Report 2024 Q4 ENG View original content: Sign in to access your portfolio
Yahoo
13-02-2025
- Business
- Yahoo
Implantica announces positive feedback received from U.S. FDA of the RefluxStop™ PMA Module 2 submission
VADUZ, Liechtenstein, Feb. 13, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that U.S. FDA has completed its review of the PMA Module 2 submission and provided its feedback, in which the company sees no barrier for responding. FDA has completed its review of the company's second modular submission of its PMA, which contained the Clinical Data, Usability Testing, and Labeling information supporting RefluxStop™. FDA has provided Implantica with its written feedback on the content submitted, all of which the company considers to be minor. A response strategy has been identified for the questions raised, and the company sees no impediment to the overall PMA approval process based on FDA's Module 2 feedback. Responses to the Module 2 feedback will be submitted in conjunction with the final Module 3 submission in the near term. Dr. Peter Forsell, Implantica's founder, CEO, and the inventor of RefluxStop, says, "We are thankful for FDA for their review of Module 2 and are pleased to receive their positive feedback on our submission thus far. Module 2 includes the results of the RefluxStop™ clinical study and is by far the most important module for this PMA from our perspective. The 5-year outcomes in conjunction with data reported in the literature are extremely positive and indicate that RefluxStop™ may revolutionize this treatment field. Implantica will, in the near term, submit the last component of our PMA application (Module 3) and work with FDA to bring RefluxStop™ to the U.S. market as soon as possible." For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@ The information was sent for publication, through the agency of the contact person set out above, on February 13, 2025, at 08:00 a.m. (CET). About ImplanticaImplantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information. About RefluxStop™ RefluxStop™ is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It's unique mechanism of action differentiates it from standard of care and current surgical solutions. Longer established surgical options for GORD involve encircling the food passageway to support the lower oesophageal sphincter's closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit. In contrast, the RefluxStop™ device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower oesophageal sphincter in its original, natural position. The RefluxStop™ mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux. Newsroomhttps:// Communityhttps:// Media Contact:Implantica AGJuanita Eberhart, VP Marketing & AdvocacyM: +1 This information was brought to you by Cision The following files are available for download: Implantica announces positive feedback received from U.S. FDA of the RefluxStopâ'¢ PMA Module 2 submission logo transparent 1 8 REFLUXSTOP View original content:
